Molecular Function
Novartis and Monte Rosa Collaborate on $2.2B Molecular Glue Degrader Alliance
Novartis, Monte Rosa, molecular glue degraders, biopharma collaboration, protein degradation, oncology, neurological diseases
Novartis Invests $150M in Monte Rosa’s Molecular Glue Technology for Autoimmune Diseases
Novartis, Monte Rosa, Molecular Glue, Protein Degradation, Autoimmune Diseases, MRT-6160, VAV1-degrader, Biotech Collaboration
Booster Therapeutics Launches with $15 Million Funding to Pioneer Proteasome Activator Therapies for Neurodegenerative Diseases
Proteasome activator therapies, Neurodegenerative diseases, Booster Therapeutics, Novo Holdings, Apollo Health Ventures, 20S proteasome, Protein degradation, Neurodegeneration
AstraZeneca Acquires Pinetree’s EGFR Degrader for $45 Million Upfront
AstraZeneca, Pinetree Therapeutics, EGFR degrader, protein degrader, oncology, licensing agreement, milestone payments, royalties, targeted protein degradation, molecular glues, cancer treatment
Syntis Bio Launches Revolutionary Oral Therapy to Mimic Weight-Loss Surgery
Syntis Bio, weight-loss surgery, oral therapy, obesity, diabetes, rare diseases, SYNT-101, gastric bypass surgery, small intestine, metabolic control, digestion, drug absorption.
Novartis’ Scemblix Demonstrates Superior Efficacy and Safety in Newly Diagnosed Leukemia Patients ###
Novartis, Scemblix, Leukemia, Chronic Myeloid Leukemia (CML), Tyrosine Kinase Inhibitors (TKIs), Gleevec, American Society of Clinical Oncology (ASCO)
Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering
Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis
Takeda Ventures into Molecular Glue Degraders with Degron Collaboration
Takeda, Degron, molecular glue degraders, pharmaceutical collaboration, targeted protein degradation, drug discovery.
Intellectual property landscape around prime editing
Intellectual Property Landscape Around Prime Editing Prime editing, a revolutionary genome editing technology, has been at the forefront of significant intellectual property developments and patent disputes. This technology, which allows for precise DNA edits without the need for double-strand breaks, was developed by Dr. David Liu and his team at the Broad Institute and Harvard […]
Enlaza Secures $100M for Groundbreaking Irreversible Protein Binding Technology
Enlaza, funding, investment, protein binding, irreversible, biotechnology, medical research, drug development, therapeutics.